

2Q.2023 Performance Results

August, 2023

This presentation has been prepared by Rayence (hereinafter "the Company), with an aim to promote investors' understanding of the Company. This presentation May not be distributed modified, reproduced in whole or in part.

The accuracy of the 'forward-looking statements' included in this presentation has not been independently verified. The forward-looking statements include projections and outlook of the Company concerning its business status and financial results, and include but not limited to words, such as 'expectation'. 'forecast', 'plan', 'anticipation' or '(E)'. The forward-looking statements are subject to changes in business environment and involve inherent risks and uncertainties.

Future expectations are based on current business environment and the Company's management direction as of the date of presentation. Future projections may differ or change due to changes in business environment or due to strategic changes by the Company,. The contents in this presentation may change with out any prior notification.

None of the Company nor ant of its respective officers assume legal responsibility for any damages or losses that may have occurred from the use of this presentation, including errors and other mistakes that may be included in this presentation

This presentation may not ne reproduced in whole or in part, nor may any of its contents be divulged to any third party, unless prior consent by the Company has been granted.

Index

1. Overview Performance

2. By Product

3. By Detector

4. Appendix

- Consolidated Income Statement

- Consolidated balance sheet, Financial ratio


1. Overview Performance

Units : Million Won	2Q.23	1Q.23	QoQ	2Q.22	YoY
Sales	37,738	37,589	+0.4%	37,626	+0.3%
Operating Profit	6,545	5,691	+15.0%	7,779	-15.9%
OPM	17.3%	15.1%	-	20.7%	-
Profit Before Tax	7,154	4,670	+53.2%	7,715	-7.3%
Net Profit	6,170	2,893	+113.3%	6,099	+1.2%

- Sales increased slightly YoY due to the growth of the animal and industrial sectors despite the weak medical sector.
- Operating profit decreased by 15.9% YoY due to increased manufacturing costs and increased SG&A expenses due to new product development.

2. By Products

Sales(Units: Million Won)



– 2Q.23 Result

- Due to the effect of launching new animal diagnostic imaging equipment in the European market, VET up 9.0% YoY
- Expanded evenly throughout, such as industrial secondary cell battery inspection equipment


Units: Million Won	2Q.23	1Q.23	QoQ	2Q.22	YoY
Dental	17,882	17,713	+1.0%	18,236	-1.9%
Medical	10,788	11,627	-7.2%	11,723	-8.0%
VET	5,982	5,641	+6.0%	5,487	+9.0%
Industries	3,064	2,535	+20.9%	2,119	+44.6%

– Strategy


- Profitability improvement through cost innovation and yield improvement
- Continued stable growth through increased supply of industrial detectors

3. By Detector


CMOS Sales& Portion(Units: Million Won)



TFT Sales& Portion(Units: Million Won)



IO Sales& Portion(Units: Million Won)



- CBCT
- AXI
- General Radiography
- Intra-oral

4. Appendix - Consolidated Income Statement



Units : Million Won	20FY	21FY	22FY	1Q.21	2Q.21	3Q.21	4Q.21	1Q.22	2Q.22	3Q.22	4Q.22	1Q.23	2Q.23
Sales	101,524	134,568	147,161	31,471	36,659	33,064	33,374	36,110	37,626	39,147	34,277	37,589	37,738
Cost of Sales	64,700	79,534	84,329	18,831	22,377	18,721	19,605	21,462	21,510	22,534	18,823	22,116	22,358
Gross Profit	36,824	55,034	62,832	12,639	14,282	14,343	13,770	14,648	16,115	16,614	15,455	15,473	15,380
Selling and administrative expenses	28,388	30,965	36,692	6,616	7,205	8,111	9,033	8,522	8,336	8,701	11,133	9,781	8,835
Operating Profit	8,436	24,069	26,139	6,023	7,077	6,232	4,737	6,126	7,779	7,912	4,322	5,691	6,545
Other Profits	135	251	2,816	1,162	173	1,789	-2,873	15	37	30	2,734	9	801
Other losses	7,942	6,271	3,608	283	3,239	3,464	-715	9	1,084	7	2,509	2,687	319
Financial income	3,365	4,941	5,438	743	192	630	3,376	1,416	1,987	4,067	-2,031	3,511	1,305
Financial losses	6,013	2,673	4,741	281	202	214	1,976	975	1,004	1,860	903	1,855	1,178
Profit Before Tax	-2,018	20,317	26,044	7,364	4,001	4,974	3,978	6,573	7,715	10,143	1,612	4,670	7,154
Tax Expense	2,059	6,224	3,412	988	3,050	1,551	635	1,540	1,616	3,392	-3,136	1,776	984
Net Profit	-4,077	14,093	22,632	6,376	950	3,423	3,344	5,033	6,099	6,751	4,749	2,893	6,170
Profit, attributable to owners of parent	-1,916	14,458	22,831	6,485	1,006	3,476	3,491	5,114	6,158	6,808	4,752	2,997	6,201
Profit, attributable to non-controlling parent	-2,161	-365	-199	-109	-56	-53	-147	-81	-58	-57	-3	-104	-31

4. Appendix - Consolidated balance sheet, Financial ratio

Units : Million Won	21FY	22FY	2Q.23
Total Asset	241,798	261,999	270,320
Cash and cash equivalents	40,201	53,231	56,314
Short-term deposits	78,124	77,500	81,500
Inventories	32,872	38,679	37,091
Tangible assets	31,393	22,742	22,221
Intangible assets	9,967	6,423	5,755
Total liabilities	42,220	36,501	36,122
Short-term trade Payables	7,661	4,491	8,352
Short-term borrowings	4,505	2,290	2,061
Other current liabilities	1,295	2,437	1,798
Long-term borrowings	-	-	-
Total Equity	199,578	225,498	234,198
Capital	8,296	8,296	8,296
Premium on common stock	107,298	107,298	107,298
Earned surplus	102,253	123,433	130,052
Current ratio	526%	699%	743%
Debt ratio	21%	16%	15%